Tango Therapeutics is a Cambridge, Mass.-based biotech focused on discovering and delivering next-generation targeted cancer therapies using the genetic principle of synthetic lethality. The company pursues three core areas: counteracting tumor suppressor gene loss, reversing cancer immune evasion, and identifying novel combination therapies. Tango intends to use the new funding to initiate clinical studies of its lead program within the next 18 months and to advance other wholly owned programs in late-stage drug discovery. The company has active strategic collaborations with Gilead Sciences that include upfront payments and program options. Tango has raised $165M in equity financing to date and has received $175M in upfront payments from collaborations. Barbara Weber, MD, serves as President and CEO, leading the company's clinical and discovery efforts. Tango Therapeutics discovers and develops targeted cancer therapies by leveraging the genetic concept of synthetic lethality. The company focuses on counteracting tumor suppressor gene loss, reversing cancer cell immune evasion, and identifying novel combination therapies. Tango plans to advance its lead program into IND-enabling studies early next year and continues multiple target identification and drug discovery efforts. The company was launched in 2017 with a $55 million Series A from Third Rock Ventures and announced a strategic collaboration with Gilead Sciences in November 2018 that included a $50 million upfront payment. Headquartered in Cambridge, Mass., Tango recently strengthened its executive team with appointments to CFO, VP of Human Resources, and VP of Business Development. The company closed an oversubscribed $60 million Series B to support its pipeline and development plans. Tango Therapeutics is a biotechnology company developing novel medicines that target context-dependent vulnerabilities in cancers using DNA sequencing and CRISPR-enabled target discovery. The company operates a product engine that applies synthetic lethality and pre-defined patient selection to discover targets and rational drug combinations for cancer subgroups. Tango is focused on three areas: vulnerabilities from loss of tumor suppressor gene function, addressing multiple oncogenic drivers through combination therapies, and targeting cancer cell genetic alterations that enable immune evasion. Its approach emphasizes using DNA sequencing of patient-derived tumor samples to define genetic contexts and deploy CRISPR-based target discovery techniques in those cancer subtypes. Tango was launched with a $55 million Series A investment from Third Rock Ventures. The company was launched in 2017 and is headquartered in Cambridge, Mass.

Total raised

$165M

Funding rounds

3

Latest round

Equity

Latest activity

Aug 2020